In vivo genome editing for inherited retinal disease: Opportunities and challenges.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Collin RWJ;Collin RWJ; Leroy BP; Leroy BP; Leroy BP; Leroy BP
  • Source:
    Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2024 Aug 07; Vol. 32 (8), pp. 2433-2434. Date of Electronic Publication: 2024 Jul 30.
  • Publication Type:
    Editorial; Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Cell Press Country of Publication: United States NLM ID: 100890581 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-0024 (Electronic) Linking ISSN: 15250016 NLM ISO Abbreviation: Mol Ther Subsets: MEDLINE
    • Publication Information:
      Publication: 2017- : Cambridge, MA : Cell Press
      Original Publication: San Diego, CA : Academic Press, 2000-
    • Subject Terms:
      Gene Editing*/methods ; Retinal Diseases*/therapy ; Retinal Diseases*/genetics ; Genetic Therapy*/methods ; CRISPR-Cas Systems*; Humans ; Animals
    • Abstract:
      Competing Interests: Declaration of interests The authors declare no competing interests.
    • Publication Date:
      Date Created: 20240731 Date Completed: 20240808 Latest Revision: 20240809
    • Publication Date:
      20240812
    • Accession Number:
      10.1016/j.ymthe.2024.07.001
    • Accession Number:
      39084223